Fount of Information

ACROBiosystems社 CD133 and New Strategies for Gastric Cancer Treatment and Management

この製品に関するご意見・ご照会・お問合せはこちら

Comprehensive_ADC_target_1.png

CAREER.png 

JOIN US  

 

Products Support Resources Insights About Us

  

  

CD133 and New Strategies for Gastric Cancer Treatment and Management

   

 

Full-length Five-pass Transmembrane Proteins

Gastric cancer is an invasive disease, and it is one of the diseases with the highest mortality in the world. Cancer stem cells (CSCs) play an important role in chemotherapy resistance, tumor initiation, invasion and metastasis. CD133 has been reported as a marker of CSCs in various tumors.

 

CD133.png

The mechanism of CD133 regulating gastric cancer progression

 

CD133 can be used as a prognostic marker as well as a biomarker of tumor spread under circulating conditions, and targeting CD133+ cells may be a potential new strategy for tumor regression. Further study of the different pathways by which cells control CD133 levels is necessary for the diagnosis and management of gastric cancer progression. 

 


 

Relying on the "FLAG" technology platforms, ACROBiosystems has developed the full-length CD133 proteins expressed by HEK293 to meet your research and development needs for targeting CD133. 

 

Product List

 

Product_List.png 

Product Advantages

 

Full-length CD133 protein with native and complete conformation

High biological activity verified by binding to antibodies

100-300 nm in size and high identity verified by DLS, can be used as an optimal target for dendritic cells and phage display

Suitable for immunization/ELISA/SPR/BLI/cell-based assay, etc.

 

 

Verification Data

Full-length CD133 (Cat. No. CD3-H52H4)

CD3-H52H4.jpg

Immobilized Human CD133, His Tag (Cat. No. CD3-H52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD133 (133-3) Antibody, Human IgG1 with a linear range of 1-16 ng/mL (QC tested).

 

Protocol.PNG

Full-length CD133 (Cat. No. CD3-H82Q8)

CD3-H82Q8.jpg

Immobilized Biotinylated Human CD133 Protein, His,Avitag (Cat. No. CD3-H82Q8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human CD133 (133-3) Antibody, Human IgG1 with a linear range of 0.2-16 ng/mL (QC tested).

 

Protocol.PNG

Full-length CD133 (Cat. No. CD3-H52H1)

CD3-H52H1.jpg

Immobilized Human CD133 Full Length, His Tag (Nanodisc) (Cat. No. CD3-H52H1) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD133 (133-3) Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).

 

Protocol.PNG

 

 

Full-length CD133 (Cat. No. CD3-H82E6)

CD3-H82E6.jpg

2e5 of Anti-CD133 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human CD133, His,Avitag (Nanodisc) (Cat. No. CD3-H82E6) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

 

Protocol.PNG

 

Click to View Other CSCs Biomarkers

  

CD20 CD24 CXCR4

 

CD47 CD44 CD117

 

EpCAM HER2 CD34

 

   

HEK293.jpgCiteAb.jpg

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。